In addition to regenerating diseased liver tissue and restoring normal liver function (particularly the liver’s protein synthesising function), three months treatment with Ropren was able to normalise lipid metabolism (cholesterol levels), improve carbohydrate metabolism through enhanced anti-oxidant activity, and restore normal levels of activity for a number of important liver and brain enzymes. Solagran is expecting a strong reaction to these results – particularly from an audience comprising specialists who are in the frontline of the fi ght against a world-wide liver disease epidemic. The fact that until the emergence of Ropren, there was no effective low-side effect treatment for serious liver diseases like cirrhosis means that its emergence will capture a great deal of attention. In addition, the fact that Solagran’s scientifi c collaborators are now able to point to a link between poor liver function and the incidence of neurodegenerative disorders, makes Ropren’s emergence particularly signifi cant – especially for developed countries facing rapid growth in the incidence of dementia.
I have a packed schedule of meetings with very senior people from academia, the medical profession, the pharmaceutical industry and the government. We also have some important decisions to make in relation to production facilities. We have a good understanding of how the demand for Ropren will develop, starting with the cities of Moscow and St Petersburg. But we need to be acting now to ensure that we have the capacity and infrastructure in place that will be required to serve the remainder of Russia and the CIS countries. One of the highlights of this trip will be a major gastroenterology conference in St Petersburg in mid-May. We have been accorded special status by the conference organisers because of the signifi cance of the introduction of Ropren into the Russian pharmacopoeia. Not only is it a paradigm-shifting drug, it is the fi rst Russian developed drug to enter the pharmacopoeia for many years.
We have also completed a trial with opiate addicted chronic alcoholics using Bioeffective® A. This trial was a replica of that conducted in 2006 using Ropren. There appears to be real potential to use both substances together in a combination therapy. We will have more to say about this once patents have been secured.
Once registration is granted in the next few weeks, our focus will switch to production and the important step of technological integration with SibEX. By August or September, we expect to be in an unassailable leadership position in relation to the science and the production of plant polyprenols.
SLA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held